Combined effects of senexin B and antitumour agents on neuroblastoma and glioblastoma cell lines
- Authors: Mazur D.V.1, Pogodaeva S.S.2, Kuchur O.A.1,2, Miletina O.O.2, Rezekina A.I.1, Petrosyan E.G.1, Rudik D.A.1, Ivanova Е.I.1, Shtil А.А.1,3, Antipova N.V.1,4
-
Affiliations:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
- ITMO University
- N.N. Blokhin National Medical Research Centre for Oncology
- National Research University “Higher School of Economics”
- Issue: Vol 51, No 3 (2025)
- Pages: 461-468
- Section: ОБЗОРНАЯ СТАТЬЯ
- URL: https://ruspoj.com/0132-3423/article/view/686964
- DOI: https://doi.org/10.31857/S0132342325030091
- EDN: https://elibrary.ru/KQNWWQ
- ID: 686964
Cite item
Abstract
Neurogenic tumors such as neuroblastoma and glioblastoma are highly heterogeneous and particularly aggressive: they are characterized by rapid growth, metastasis and resistance to treatment. Both tumors exhibit MYCN oncogene copy-number disruption, impaired gene transcription, and overall high transcriptional deregulation. In this study, we evaluated the survival of glioblastoma and neuroblastoma cells and performed real-time PCR analysis to assess the change in expression of MYCN, HAND2, PHOX2A, and PHOX2B oncogenes after exposure to senecin B in combination with temozolomide and the potential therapeutic agent 10058-F4. As a result, a trend of increased PHOX2B gene expression and decreased PHOX2A gene expression after drug exposure was observed in one of the neuroblastoma lines and both glioblastoma lines, an increase in MYCN and HAND2 gene expression was also observed. Viability tests showed that substance 10058-F4 was effective against neuroblastoma line but not glioblastoma lines. However, senexin B enhanced the inhibitory effect of 10058-F4 on glioblastoma cell lines and also enhanced the effect of temozolomide on the T98G cell line.
Keywords
Full Text

About the authors
D. V. Mazur
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997
S. S. Pogodaeva
ITMO University
Email: nadine.antipova@gmail.com
Russian Federation, Kronverksky prosp. 49, liter A, St. Petersburg, 197101
O. A. Kuchur
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; ITMO University
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997; Kronverksky prosp. 49, liter A, St. Petersburg, 197101
O. O. Miletina
ITMO University
Email: nadine.antipova@gmail.com
Russian Federation, Kronverksky prosp. 49, liter A, St. Petersburg, 197101
A. I. Rezekina
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
Russian Federation, 117997 Москва, улица Миклухо-Маклая, 16/10
E. G. Petrosyan
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997
D. A. Rudik
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997
Е. I. Ivanova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997
А. А. Shtil
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; N.N. Blokhin National Medical Research Centre for Oncology
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997; Kashirskoye shosse 23, Moscow, 115522
N. V. Antipova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, RAS; National Research University “Higher School of Economics”
Author for correspondence.
Email: nadine.antipova@gmail.com
Russian Federation, ul. Miklukho-Maklaya 16/10, Moscow, 117997; ul. Profsoyuznaya 33/4, Moscow, 101000 Russia
References
- Boeva V., Louis-Brennetot C., Peltier A., Durand S., Pierre-Eugène C., Raynal V., Etchevers H.C., Thomas S., Lermine A., Daudigeos-Dubus E., Geoerger B., Orth M.F., Grünewald T.G.P., Diaz E., Ducos B., Surdez D., Carcaboso A.M., Medvedeva I., Deller T., Janoueix-Lerosey I. // Nat. Genet. 2017. V. 49. P. 1408–1413. https://doi.org/10.1038/ng.3921
- Jacob F., Salinas R.D., Zhang D.Y., Nguyen P.T.T., Schnoll J.G., Wong S.Z.H., Thokala R., Sheikh S., Saxena D., Prokop S., Liu D.-A., Qian X., Petrov D., Lucas T., Chen H.I., Dorsey J.F., Christian K.M., Binder Z.A., Nasrallah M., Song H. // Cell. 2020. V. 180. P. 188–204. https://doi.org/10.1016/j.cell.2019.11.036
- Karadkhelkar N.M., Lin M., Eubanks L.M., Janda K.D. // J. Am. Chem. Soc. 2023. V. 145. P. 3259– 3269. https://pubs.acs.org/doi/10.1021/jacs.2c12732
- Müller I., Larsson K., Frenzel A., Oliynyk G., Zirath H., Prochownik E.V., Westwood N.J., Henriksson M.A. // PLoS One. 2014. V. 9. P. e97285. https://doi.org/10.1371/journal.pone.0097285
- Bjerke L., Mackay A., Nandhabalan M., Burford A., Jury A., Popov S., Bax D.A., Carvalho D., Taylor K.R., Vinci M., Bajrami I., McGonnell I.M., Lord C.J., Reis R.M., Hargrave D., Ashworth A., Workman P., Jones C. // Cancer Discov. 2013. V. 3. P. 512–519. https://doi.org/10.1158/2159-8290.CD-12-0426
- Hodgson J.G., Yeh R.-F., Ray A., Wang N.J., Smirnov I., Yu M., Hariono S., Silber J., Feiler H.S., Gray J.W., Spellman P.T., Vandenberg S.R., Berger M.S., James C.D. // Neuro Oncol. 2009. V. 11. P. 477–487. https://doi.org/10.1215/15228517-2008-113
- Čančer M., Drews L.F., Bengtsson J., Bolin S., Rosén G., Westermark B., Nelander S., Forsberg-Nilsson K., Uhrbom L., Weishaupt H., Swartling F.J. // Cell Death Dis. 2019. V. 10. P. 881. https://doi.org/10.1038/s41419-019-2120-1
- Wang B., Wu Z.-H., Lou P.-Y., Chai C., Han S.-Y., Ning J.-F., Li M. // Cell Oncol. 2019. V. 42. P. 783–799. https://doi.org/10.1007/s13402-019-00461-z
- Liang J., Chen M., Hughes D., Chumanevich A.A., Altilia S., Kaza V., Lim C.-U., Kiaris H., Mythreye K., Pena M.M., Broude E.V., Roninson I.B. // Cancer Res. 2018. V. 78. P. 6594–6606. https://doi.org/10.1158/0008-5472.can-18-1583
- Sharko A.C., Lim C.-U., McDermott M.S.J., Hennes C., Philavong K.P., Aiken T., Tatarskiy V.V., Roninson I.B., Broude E.V. // Cells. 2021. V. 10. P. 144. https://doi.org/10.3390/cells10010144
- Ding X., Sharko A.C., McDermott M.S.J., Schools G.P., Chumanevich A., Ji H., Li J., Zhang L., Mack Z.T., Sikirzhytski V., Shtutman M., Ivers L., O’Donovan N., Crown J., Győrffy B., Chen M., Roninson I.B., Broude E.V. // Proc. Natl. Acad. Sci. USA. 2022. V. 119. P. e2201073119. https://doi.org/10.1073/pnas.2201073119
- Zaatiti H., Abdallah J., Nasr Z., Khazen G., Sandler A., Abou-Antoun T.J. // Int. J. Oncol. 2018. V. 52. P. 787– 803. https://doi.org/10.3892/ijo.2018.4236
- Mercatelli D., Balboni N., Palma A., Aleo E., Sanna P.P., Perini G., Giorgi F.M. // Biomolecules. 2021. V. 52. P. 177. https://doi.org/10.3390/biom11020177
- Moody C.L., Wheelhouse R.T. // Pharmaceuticals (Basel). 2014. V. 7. P. 797–838. https://doi.org/10.3390/ph7070797
- McDermott M.S.J., Chumanevich A.A., Lim C.-U., Liang J., Chen M., Altilia S., Oliver D., Rae J.M., Shtutman M., Kiaris H., Győrffy B., Roninson I.B., Broude E.V. // Oncotarget. 2017. V. 8. P. 12558–12575. https://doi.org/10.18632/oncotarget.14894
- Li J., Hilimire T.A., Liu Y., Wang L., Liang J., Gyorffy B., Sikirzhytski V., Ji H., Zhang L., Cheng C., Ding X., Kerr K.R., Dowling C.E., Chumanevich A.A., Mack Z.T., Schools G.P., Lim C.-U., Ellis L., Zi X., Chen M. // J. Clin. Invest. 2024. V. 134. P. e176709. https://doi.org/10.1172/jci176709
Supplementary files
